Navigation Links
96-Well Filtration Plate From Varian, Inc. Improves Sensitivity and Precision for Trace Bio-Analysis by LC/MS
Date:9/1/2008

PALO ALTO, Calif., Sept. 1 /PRNewswire-FirstCall/ -- Varian, Inc. (NasdaqGS: VARI) announced today its new filtration plate for sample preparation. Captiva(TM) NDLipids is a simple to use, non-drip 96-well plate specially designed to remove phospholipids including lysophosphatidylcholines, from biofluids.

It is intended for use by analytical chemists in the pharmaceutical and life science industries performing quantitative and qualitative analyses of drugs in biofluids. In applications such as drug screening and monitoring in early discovery, pre-clinical and clinical trials, the lipids, proteins and surfactants in a biofluid sample must be removed before analysis by liquid chromatography/mass spectroscopy (LC/MS). Incomplete removal leads to ion suppression (reduced sensitivity) and, over time, degrades the performance of both the LC column, reducing column life, and the MS ion source, increasing maintenance.

Using Captiva NDLipids, plasma extracts are virtually free from endogenous matrix interferences (over 97% of the phosphatidylcholines are removed). Ion suppression is significantly reduced resulting in enhanced sensitivity and precision during trace analysis. The removal of lipid compounds results in better peak shapes and more reproducible retention times so that Standard Operating Procedure (SOP) parameters are easily validated. A fast, 3-step, in-well precipitation protocol is applicable to a wide variety of analytes. This ensures high sample throughputs and avoids the need for extensive methods development.

"Captiva NDLipids is a double win for our customers," said Martin O'Donoghue, Senior Vice President, Scientific Instruments, Varian, Inc. "The efficient removal of matrix interferences offers improved analytical sensitivity, and the simple clean up method leads to productivity enhancements."

For more technical information about Varian products, please visit http://www.varianinc.com/products/

Varian, Inc. is a leading worldwide supplier of scientific instruments and vacuum technologies for life science and industrial applications. The company provides complete solutions, including instruments, vacuum products, laboratory consumable supplies, software, training and support through its global distribution and support systems. Varian, Inc. employs approximately 4,000 people worldwide and operates manufacturing facilities in North America, Europe and Asia Pacific. Varian, Inc. had fiscal year 2007 sales of $921 million, and its common stock is traded on the NASDAQ Global Select Market under the symbol, "VARI." Further information is available on the company's Web site: http://www.varianinc.com.

For More Information, Contact:

Public Relations

Varian, Inc.

650.424.3845

pr@varianinc.com


'/>"/>
SOURCE Varian, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
2. DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) or Aspirin
3. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
4. New Data Show High Frequency of Medical Claims for Gastrointestinal Events by Patients on Antiplatelet Therapy
5. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
6. Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy
7. SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
8. Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting
9. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
10. American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
11. Hibernation-On-Demand Drug Hydrogen Sulfide Significantly Improves Survival After Extreme Blood Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)...   Divoti USA will engrave and process ... of the latest FDA requirements, which stipulates new criteria regarding medical ... need of Medical ID jewelry such as Medical ID Bracelets, can ... in terms of the new FDA requirements . ... Divoti offers this dark mark fiber laser ...
(Date:10/11/2017)...  BioPharmX Corporation (NYSE MKT: BPMX) researchers were part ... way to use nonlinear optical imaging to confirm the ... A presentation ... how researchers from BioPharmX and the Wellman Center for ... suite of imaging techniques in what is called "Pharmacokinetic ...
(Date:10/11/2017)... FRISCO, Texas , Oct. 11, 2017 /PRNewswire/ ... healthcare services, has amplified its effort during National ... patients about hereditary cancer risks. ... Journal of Clinical Oncology calculated that more than ... to have inherited mutations in BRCA1 or BRCA2 and ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Arkansas that offers insurance and financial preparation services, is providing an update on ... Rescue organization. , Rock City Rescue is a locally recognized nonprofit that provides ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family ... next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. ... 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the ...
(Date:10/13/2017)... EDWARDSVILLE, Ill. (PRWEB) , ... ... ... University Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and ... educated healthcare professionals on guideline updates for the primary prevention of cardiovascular ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids this ... by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited about ... ages; it is a non-competitive, non-timed event, which is all about having fun and ...
Breaking Medicine News(10 mins):